Source comparison
MOTS-c Work for Mitochondrial-Derived Peptide Research: Full Comparison
This table compares MOTS-c to other mitochondrial interventions used in research. MOTS-c AMPK activation + nuclear translocation under stress 1.5 mg/kg 2× weekly (human); 5 mg/kg 3× weekly (rodent) Moderate. Phase 1/2 human trials, extensive rodent data Yes, w
This comparison does not assign a generated winner or score.
- This table compares MOTS-c to other mitochondrial interventions used in research.
- MOTS-c
- AMPK activation + nuclear translocation under stress
- 1.5 mg/kg 2× weekly (human); 5 mg/kg 3× weekly (rodent)
- Moderate. Phase 1/2 human trials, extensive rodent data
- Yes, with adjusted dosing frequency
- Strongest evidence among MDPs; requires proper storage and dosing schedule
- Humanin
- Apoptosis inhibition, neuroprotection
- 2–4 mg/kg daily (rodent)
- Low. Rodent models only, no human RCTs
- Unknown. No human trial data
- Promising neuroprotective effects in vitro but lacks clinical validation
- NAD+ precursors (NR, NMN)
- NAD+ repletion for sirtuin activation
- 250–1000 mg daily (human)
- Moderate. Multiple human trials, mixed results
- Yes, but effect sizes modest
- Well-tolerated; increases NAD+ levels reliably but downstream metabolic benefits inconsistent
- CoQ10
- Electron transport chain cofactor
- 100–600 mg daily (human)
- High. Decades of clinical use
- Yes, especially in mitochondrial disorders
- Gold standard for mitochondrial support; no gene-regulatory function
- Metformin
- Complex I inhibition → AMPK activation
- 500–2000 mg daily (human)
- Very high. Used clinically for decades
- Yes, extensively validated
- AMPK activation similar to MOTS-c but through different upstream pathway; more side effects (GI, lactic acidosis risk)